Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto


6.32   0.87 (15.96%) 02-23 16:00
Open: 5.21 Pre. Close: 5.45
High: 6.32 Low: 5.18
Volume: 271,721 Market Cap: 166(M)

Technical analysis

as of: 2023-03-03 4:50:22 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 7.38     One year: 8.62
Support: Support1: 4.82    Support2: 3.9
Resistance: Resistance1: 6.32    Resistance2: 7.38
Pivot: 5.3
Moving Average: MA(5): 5.49     MA(20): 5.07
MA(100): 4.25     MA(250): 2.54
MACD: MACD(12,26): 0.3     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 87.2     %D(3): 81.4
RSI: RSI(14): 75.3
52-week: High: 6.32  Low: 0.97
Average Vol(K): 3-Month: 114 (K)  10-Days: 119 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IMRA ] has closed Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.32 - 6.34 6.34 - 6.36
Low: 5.13 - 5.15 5.15 - 5.17
Close: 6.27 - 6.31 6.31 - 6.35

Company Description

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 15 Mar 2023
An army of Big Pharma companies is backing new startup out of ... - The Business Journals

Wed, 22 Feb 2023
Imara Announces Stockholder Approval of Merger With Enliven - GlobeNewswire

Fri, 06 Jan 2023
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch - Penny Stocks

Fri, 14 Oct 2022
SHAREHOLDER ALERT: Weiss Law Investigates IMARA Inc. - KALB

Thu, 13 Oct 2022
Dow Futures Tick Higher After Indices Stage Major Reversal - Yahoo Finance

Thu, 13 Oct 2022
Enliven Therapeutics and Imara Announce Merger Agreement - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 26 (M)
Shares Float 9 (M)
% Held by Insiders 16.6 (%)
% Held by Institutions 71.3 (%)
Shares Short 341 (K)
Shares Short P.Month 1,370 (K)

Stock Financials

EPS -2.5
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.77
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -34.2
Return on Equity (ttm) -57.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.71
Qtrly Earnings Growth 0
Operating Cash Flow -46 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -2.54
PEG Ratio 0
Price to Book value 1.67
Price to Sales 0
Price to Cash Flow -3.6

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.